Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NGC-Cap
- Development stage
- Unknown
- Lead developer
- Processa Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NGC-Cap is a combination therapy developed by Processa Pharmaceuticals that consists of the irreversible dihydropyrimidine dehydrogenase (DPD) enzyme inhibitor PCS6422 and low-dose capecitabine, an oral prodrug of 5-fluorouracil (5-FU). The addition of PCS6422 inhibits DPD-mediated catabolism of 5-FU, resulting in increased exposure of cancer cells to the active metabolite and reduced formation of toxic byproducts. This approach aims to enhance anti-tumor efficacy while reducing side effects compared to standard capecitabine monotherapy. NGC-Cap is being developed primarily for advanced or metastatic breast cancer and has also shown activity in gastrointestinal cancers. Clinical trials have demonstrated improved safety profiles and preliminary efficacy signals over conventional regimens[1][3][4][5][6][7][8].
- Brand names
- NGC-Cap
- Other names
- Next Generation CapecitabineCapecitabine administered with PCS6422
02
Targets
TS (Thymidylate synthase)DPYD (Dihydropyrimidine dehydrogenase)
Beyond the preview
Go deeper on NGC-Cap.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGC-Cap.